Extended Data Fig. 5: Efficacy and specificity of Syk inhibitors.
From: Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia
a. Cellular efficacy of WC35, WC36, and WC38 was determined by dose-dependent inhibition of Syk phosphorylation in Raji B cells. b. Imax and IC50 values (see Supplementary Table 3) were determined by nonlinear least-squares analysis of data using the equation: I = Imax / (1 + IC50 / [inhibitor]) where I indicates %inhibition. %inhibition was calculated by 100 x (relative decrease in pSyk/(total Syk) at a given inhibitor concentration ([inhibitor]) compared to that without an inhibitor. Each data represents average ± SD from 3 independent measurements. c. Specificity of WC35, WC36, WC38, and entospletinib (ENTO) was determined by measuring the inhibition of ZAP70 phosphorylation by these molecules (5 μM overnight) in Jurkat T cells. Jurkat T cells were stimulated by OKT3. Each gel image is a representative of 3 independent experiments.
